Device Firms Seek More Exemptions, Pricing Flexibility For Oncoming Excise Tax
This article was originally published in The Pink Sheet Daily
Written comments were due May 7 on the Internal Revenue Service’s proposed regulation to implement a 2.3% excise tax on device sales in the lead-up to a May 16 public hearing.
You may also be interested in...
AdvaMed aims to “decouple” discussion of the device tax from the health care reform debate and link its repeal to broader efforts focused on improving the U.S. tax system.
IRS issued the draft regulation in the lead up to the Jan. 1, 2013, launch date of the 2.3% federal excise tax on most U.S. device sales, enacted in 2010 under the Affordable Care Act. The agency is collecting comments on the proposal through May and will hold a public meeting May 16.
Industry survey outlines challenges of globalization cited by medtech execs, including potential for insufficient supply chain visibility. Report suggests IT improvements and “on-demand visibility” solutions could help iron out the kinks.